Jean-Didier Bosenge-Nguma

Jean-Didier Bosenge-Nguma

Auto-generated profile, based on publicly available information

Jean-Didier Bosenge-Nguma

Department of Obstetrics and Gynaecology, Faculty of Medicine and Pharmacy, University of Kisangani, Kisangani, Democratic Republic of the Congo

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2025 in Monash Bioethics Review
Verified
Journal Article
Closed access
PDF file
ACAlexis Heng Boon Chin
Alexis Heng Boon Chin
JRJon Rueda
Jon Rueda
NSNingyu Sun
Ningyu Sun
TDTruc Ngoc Hoang Dang
Truc Ngoc Hoang Dang
JBJean Didier Bosenge-Nguma
Jean Didier Bosenge-Nguma
SMSayyed Mohamed Muhsin
Sayyed Mohamed Muhsin

18 July 2023 in Contraception and Reproductive Medicine
Verified
Journal Article
Open access
PDF file
JBJean-Didier Bosenge-Nguma
Jean-Didier Bosenge-Nguma
AOAntoine Modia O’yandjo
Antoine Modia O’yandjo
JSJuakali Sihalikyolo
Juakali Sihalikyolo
NONoël Labama Otuli
Noël Labama Otuli
KNKadima Ntokamunda
Kadima Ntokamunda
KBKatenga Bosunga
Katenga Bosunga
Background: In sub-Saharan Africa, tubal factors are described as the main aetiological factors of infertility. Under these conditions, medically assisted procreation is particularly indicated. However, Assisted Reproductive Technology centres are less available. Thus, infertile couples are quickly oriented towards available alternative conventional treatments. The present study aimed to determine the aetiological factors of infertility, the outcomes of the therapeutic options offered, and the factors associated with the success of conventional treatment among infertile couples seeking tertiary care in Kisangani. Methods: A cross-sectional study was conducted at two tertiary health facilities in Kisangani. Infertile couples who provided consent underwent specific examinations necessary for the exploration of infertility and were treated and followed up for a minimum of 6 months. The therapeutic options that were offered were expectant attitude, medical treatment, surgical treatment or transfer to an in vitro fertilization unit. The pregnancy diagnosis was performed by ultrasound. Results: A total of 272 infertile couples underwent specific examinations, were treated and were followed up for a minimum of 6 months. Many determinant causes were mostly linked to wives rather than husbands. Overall, only 34 women among 211 who were treated became pregnant during the follow-up period; 61 couples were advised to resort to IVF or adoption, but the couples for whom expectant the attitude was indicated immediately rejected it. The patients who therapeutically succeeded at the end of the treatment were those who were younger than 35 years (OR = 2.27; 95% CI = 1.06–4.87; P = 0.017), had a duration of infertility of less than five years (OR = 6.08; 95% CI = 1.79–20.69; P = 0.001) and had secondary infertility (OR = 6.08; 95% CI = 1.79–20.69; P = 0.001). Conclusion: Kisangani faces a major issue in the treatment of infertility. Treatment of patients using conventional methods is limited by the predominance of tubal factors as aetiological determinants of infertility. The low pregnancy rate found in this study provided additional evidence of this. This paper represents a serious plea to national policy-makers to encourage them to pay attention to issues surrounding infertility.


4 January 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
NONoël Labama Otuli
Noël Labama Otuli
RDRoland Marini Djang'EIng'A
Roland Marini Djang'EIng'A
JLJoris LOSIMBA LIKWELA
Joris LOSIMBA LIKWELA
JNJean‐Didier Bosenge Nguma
Jean‐Didier Bosenge Nguma
MAMike‐Antoine Maindo Alongo
Mike‐Antoine Maindo Alongo
JOJean‐Pascal Manga Okenge
Jean‐Pascal Manga Okenge

28 June 2024 in Cureus
Verified
Journal Article
Open access
PDF file
JBJean-Didier Bosenge-Nguma
Jean-Didier Bosenge-Nguma
AOAntoine Modia O'Yandjo
Antoine Modia O'Yandjo
RDRoland Marini Djang'Eing'A
Roland Marini Djang'Eing'A
JSJuakali Skv
Juakali Skv
NONoël Labama Otuli
Noël Labama Otuli
GBGédéon Katenga Bosunga
Gédéon Katenga Bosunga
Background: Both sildenafil and estradiol are seen to improve endometrial thickness in patients with infertility who are undergoing clomiphene induction cycles. However, the correlation between endometrial thickness and pregnancy rate is debatable. This study investigated the effect of adding oral sildenafil to clomiphene citrate (CC), compared to adding estradiol valerate, on the uterine biophysical profile (Applebaum score) and pregnancy rate. Methods: This was a double-blinded, randomized controlled trial conducted in Kisangani in the Democratic Republic of the Congo from October 1, 2021, to October 31, 2023. Patients with unexplained infertility were randomly assigned to one of two groups: the interventional, which was given CC (2 x 50 mg/day from day 3 to day 7 of the menstrual cycle) + sildenafil (2 x 25 mg/day orally from day 8 to day 12) or (ii) the control group, which was given CC (similar dosage as the intervention group) + EV (2 x 2 mg/day orally from day 8 to day 12), for a maximum of three cycles. Applebaum scores and clinical pregnancy rates were measured. Results: Patients in the sildenafil and EV groups were similar in mean age (29.04 versus 28.89 years). Of the 74 patients enrolled in each group, 71 in the sildenafil group and 72 in the EV group received treatment and were followed to completion. The Applebaum scores were significantly higher in the sildenafil group than in the EV group (17.05 versus 15.14, respectively, P=0.000). In the sildenafil group, the clinical pregnancy rate was also significantly higher, at 28.92% versus 20.83% in the EV group (P = 0.04). Conclusion: As compared to EV, the oral addition of sildenafil to CC is associated with a good Applebaum score and a high rate of clinical pregnancy in patients with unexplained infertility.

9 October 2024 in Contraception and Reproductive Medicine
Verified
Journal Article
Open access
PDF file
JBJean-Didier Bosenge-Nguma
Jean-Didier Bosenge-Nguma
AOAntoine Modia O’yAndjo
Antoine Modia O’yAndjo
RDRoland Marini Djang’eIng’a
Roland Marini Djang’eIng’a
JSJuakali Skv
Juakali Skv
NONoël Labama Otuli
Noël Labama Otuli
GBGédéon Katenga Bosunga
Gédéon Katenga Bosunga
This study aimed to assess the effect of sildenafil citrate and estradiol valerate as adjuvant therapy during ovarian stimulation cycles with clomiphene citrate in patients with unexplained infertility in Kisangani. A double-blind, randomized controlled trial was conducted for two years at two specialized health facilities in Kisangani (University Clinics of Kisangani and “Clinique des Anges Kisangani”). The population included 148 patients, 74 of whom were on clomiphene citrate + sildenafil citrate (CCSC) regimens and 74 of whom were on clomiphene citrate + estradiol valerate (CCEV) regimens for three months. The primary indicator was the conception rate, with secondary outcomes encompassing endometrial thickness, appearance and vascularity, the number of mature follicles and ovulation rate. The two groups were comparable in terms of sociodemographic and clinical characteristics. The mean duration of attempting to conceive was 4.39 years versus 4.36 years (P = 0.839), while the mean AFC was 11.51 versus 11.46 (P = 0.831), in the CCSC group versus CCEV group respectively. Secondary infertility was the most frequent diagnosis in each of the two groups. The biochemical pregnancy rate was comparable between the two groups (P = 0.385), while the clinical pregnancy rate was significantly higher in the CCSC group versus CCEV group (P = 0.04). Both perifollicular flow and the ovulation rate were significantly higher in the CCSC group versus the CCEV group (P = 0.006 and P = 0.002 respectively). However, endometrial vascularity/thickness, and the number of Graafian follicles were not significantly different between the two groups. As an adjuvant, sildenafil increases the rate of clinical pregnancy more than does estradiol in patients with unexplained infertility undergoing ovarian stimulation with clomiphene citrate. PACTR 202,310,849,449,401 (Pan African Clinical Trials Registry).